



PTO/SB/08B(10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

of

**Complete if Known**

Application Number	10/623,162
Filing Date	07/18/03
First Named Inventor	Richard B. Silverman
Group Art Unit	1621
Examiner Name	
Attorney Docket Number	7123

**OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
PRC	AA	Lippert, B.; Metcalf, B. W.; Jung, M. J.; Casara, P. 4-Amino-hex-5-enoic acid, a selective catalytic inhibitor of 4-aminobutyric-acid aminotransferase in mammalian brain. <i>Eur. J. Biochem.</i> 1977, 74, 441-445.	
	AB	Dewey, S. L.; Morgan, A. E.; Ashby, C. R., Jr.; Horan, B.; Kushner, S. A.; Logan, J.; Volkow, N. D.; Fowler, J. S.; Gardner, E. L.; Brodie, J. D. A novel strategy for the treatment of cocaine addiction. <i>Synapse</i> 1998, 30, 119-129.	
	AC	Dewey, S. L.; Brodie, J. D.; Gerasimov, M.; Horan, B.; Gardner, E. L.; Ashby, C. R., Jr. A pharmacologic strategy for the treatment of nicotine addiction. <i>Synapse</i> 1999, 31, 76-86.	
	AD	Gerasimov, M. R.; Ashby, C. R.; Gardner, E. L.; Mills, M. J.; Brodie, J. D.; Dewey, S. L. Gamma-vinyl GABA inhibits methamphetamine, heroin, or ethanol-induced increases in nucleus accumbens dopamine. <i>Synapse</i> 1999, 34, 11-19.	
PRC	AE	Pan, Y.; Qiu, J.; Silverman, R. B. Design, synthesis, and biological activity of a difluoro-substituted, conformationally rigid vigabatrin analogue as a potent $\gamma$ -aminobutyric acid aminotransferase inhibitor. <i>J. Med. Chem.</i> 2003, 46, 5292-5293.	

Examiner  
SignatureDate  
Considered

5.4.04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.  
MW:1055198AMH:KAB